LOS ANGELES, June 2, 2005 (PRIMEZONE) -- BiomedDiscoveries.com, http://www.BiomedDiscoveries.com, the online source for exclusive investor information in the biotechnology sector, has announced the availability of an online interview with Michael Weiner, CEO of Biophan Technologies (OTCBB:BIPH), a developer of next-generation medical technology.
Biophan has recently announced the filing of 13 new patent applications, expanding its intellectual property portfolio to 127 U.S. issued, pending, and exclusively licensed patents, in addition to 46 international issued and pending patents.
In the interview, Mr. Weiner focuses on the Company's new patent applications, which he describes as varying in scope and detail, but all integral to the Company's "patent thicket" business strategy to ensure market leadership. That strategy seeks to safeguard Biophan's intellectual property and minimize any chances of copycat competition by casting a wide patent net around its technological innovations.
The technologies described in its new patent applications expand Biophan's coverage of nanomagnetic and other device coatings, specialized dielectric materials, biothermal power sources, certain photonic diagnostics and therapies, and other innovations. Many of the Company's technologies provide solutions to ensure safety and image compatibility of implanted and interventional medical devices with Magnetic Resonance Imaging (MRI) diagnostic equipment.
A growing body of published medical research is drawing attention to the need for improved safety and visualization of MRI imaging with pacemakers and other implanted devices, many of which are currently contraindicated for use in MRI systems. The electromagnetic environments of MRI can cause many of these devices to heat up dangerously, to create induced voltages, or to malfunction, potentially causing serious harm or death to patients. Other devices such as stents are safe for use with MRI, but interfere with imaging by MRI, which limits their functionality. Biophan has technologies to address both of these limitations.
In the interview, Mr. Weiner also discusses the relative economic efficiency of the Company's research and development initiatives, noting that most technology companies typically spend far more to develop their intellectual property on a per-patent basis. The interview is available online at http://www.BiomedDiscoveries.com.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 127 U.S. patents, licenses, or applications. This total includes 36 issued U.S. patents, 9 recently-allowed applications that will issue as patents in the near future, and 82 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
About BiomedDiscoveries.com
BiomedDiscoveries.com provides exclusive commentary, research, interviews and other information about the smallcap investment marketplace. BiomedDiscoveries.com strives to provide investors with information and research-based data regarding important individual companies and overall marketplace trends. Resources available on BiomedDiscoveries.com include audio interviews with corporate leaders and respected commentators, as well as technical white papers and other forms of market and investment analysis. It is located at http://www.BiomedDiscoveries.com.
Forward-Looking Statements
Statements made on BiomedDiscoveries.com may contain forward-looking statements made by senior management of the companies presented here that involve risks and uncertainties, such as statements about plans, objectives, expectations, assumptions or future events. These statements involve estimates, assumptions, known and unknown risks, uncertainties and performances, or achievements expressed or implied by the forward-looking statements. Actual future results and trends may differ materially from those made in -- or suggested by -- statements presented here due to a variety of factors. Consequently, you should not place undue reliance on any forward-looking statements made here. Many of these and other risks and uncertainties are discussed in greater detail in recent filings with the Securities Exchange Commission for the companies that are present by BiomedDiscoveries.com. Compensation and Other Disclosures BiomedDiscoveries.com is a wholly-owned subsidiary of Trilogy Capital Partners, Inc. Trilogy Capital Partners provides investor relations services to public companies. The companies presented by BiomedDiscoveries.com are usually clients of Trilogy Capital Partners and compensate Trilogy Capital Partners for these services, including cash compensation and equity securities. In addition, Trilogy Capital Partners and its affiliates may own securities of the presenting companies, and may from time to time purchase and sell securities of these companies in the open market or in private transactions. Biophan Technologies pays Trilogy $12,500 per month for so long as Trilogy is retained to provide investor relations services. A subsidiary of Trilogy has entered into an agreement with a non-affiliate shareholder of this company to purchase from the shareholder 880,000 shares at $.80 per share and 4,180,000 shares at $2.00 per share at such time as the shareholder has purchased the shares from by this company at the same prices. The shareholder is obligated to purchase these shares only if this company has registered the shareholder's resale of the shares under the Securities Act of 1933 and certain other conditions are satisfied.